Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hodgkin Disease 7Sarcoma 6Neoplasms 6Hematologic Neoplasms 6Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Neuroblastoma 4Multiple Myeloma 4Lymphoma, Mantle-Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Myeloproliferative Disorders 3Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Vomiting 2Testicular Neoplasms 2Recurrence 2Osteosarcoma 2Neoplasm Metastasis 2Nausea 2Burkitt Lymphoma 2Thalassemia 1Teratoma 1Seminoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Ovarian Germ Cell Cancer 1

Interventions

Cyclophosphamide 66Rituximab 43fludarabine phosphate 37Methotrexate 36Whole-Body Irradiation 34Peripheral Blood Stem Cell Transplantation 34Vincristine 33Etoposide 32Cytarabine 29Mycophenolic Acid 28Tacrolimus 23Busulfan 23Prednisone 22Doxorubicin 22Filgrastim 21merphos 20Dexamethasone 20Cyclosporine 19Melphalan 18Calcium Dobesilate 18Granulocyte Colony-Stimulating Factor 17Antilymphocyte Serum 17Radiotherapy 16Leucovorin 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 13prednylidene 12deltacortene 12azathiopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Burkitt Lymphoma × Mesna × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00126191 2013-05-23

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 9 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡